On October 29, 2021 Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, reported that it will present multiple posters on its lead program, ST101, at the 28th Prostate Cancer Foundation (PCF) Annual Scientific Retreat, being held virtually October 28- 29th, 2021 and November 4-5, 2021, and the 18th International Congress of the Society for Melanoma Research, being held virtually October 28-31, 2021 (Press release, Sapience Therapeutics, OCT 29, 2021, View Source [SID1234592199]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details for the posters are as follows:

Society for Melanoma Research

Presentation Title: Efficacy, safety, PK and PD data from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with advanced and metastatic solid tumors
Date/Time: October 28, 2021 from 3:00 PM-4:30 PM ET

Presentation Title: C/EBPβ antagonist peptide, ST101, as a novel therapeutic for melanoma
Date/Time: October 28, 2021 from 3:00 PM-4:30 PM ET
PCF Annual Scientific Retreat

Presentation Title: Efficacy, safety, pharmacokinetic and pharmacodynamic data from phase 1 dose-escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with castration-resistant prostate cancer
Date/Time: November 4, 2021 from 1:00 PM-2:30 PM PT

Presentation Title: Cell-penetrating peptide antagonist of CCAAT/enhancer binding protein β displays potent anti-prostate cancer activity
Date/Time: October 29, 2021 from 12:30 PM-2:00 PM ET
About ST101
ST101, a peptide antagonist of C/EBPβ, is currently being evaluated in an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors (NCT04478279). In the ongoing study, ST101 has demonstrated clinical proof-of-concept with a RECIST 1.1-confirmed partial response (PR) in a patient with cutaneous melanoma and evidence of long-lasting stable disease in several additional patients. Following conclusion of the final dose-escalation cohort, Sapience plans to initiate four Phase 2 expansion cohorts in refractory, locally advanced and metastatic cutaneous melanoma, hormone-receptor-positive breast cancer, castrate-resistant prostate cancer, and glioblastoma starting in the second half of 2021. ST101 has been granted orphan drug product designation from the U.S. Food and Drug Administration and orphan medicinal product designation for the treatment of glioma by the European Commission.